- Achieved $2.3M in revenue in 2018 (unaudited)
- Performed roughly 2% of all whole genomes sequenced in the world in 2018 (estimated based on 3rd party research)
- Member of the Startup Health Academy, WeWork Labs accelerator, and Amazon Launchpad
- Established relationships with prestigious universities such as King's College London and Imperial College
- Total Amount Raised: US $506,567
- Total Round Size: US $3,000,000
- Series A :
- Minimum Investment: US $10,000 per investor
- : Crowd Note
- US $15,000,000 :
We believe genomics will power personalized medicine and the discovery of the next generation of disease treatment and preventive medicine. Whole genome sequencing is a comprehensive genetic test. We sell whole genome sequencing tests to individuals with conditions that can benefit from the test, and provide these individuals with advanced analytics and personalized reports based on their medical background.
In 2018, we performed 2% of all whole genomes sequenced in the world (8,000 out of an estimated 400,000), reaching customers in more than 84 countries. We established relationships with prestigious universities such as King's College London and Imperial College. We developed specialized skills in whole genome sequencing and analysis and built barriers to entry.
In 2019, we launched our first commercially available long-read whole genome sequencing, based on Oxford Nanopore technology, and became a Nanopore-certified service provider. We are now opening a global 9,000 square foot, high-throughput, automated sequencing center in Italy, with both short-read and long-read sequencing. Based on our estimates, this center will allow us to decrease our costs and turnaround time to 2-3 weeks vs. 8-10 weeks, and to offer premium services to customers that require quicker turnaround.
All our reports are generated internally. We have developed our proprietary internal data analytics tools and report engine. Today, we control our pipeline from shipment of sample collection kits, to sample receiving, sequencing, bioinformatics, and report generation.
We have achieved these milestones raising less than $1M. We are now ready to grow. We project that we will become profitable in 2020.
Our product offering leverages our extensive investments in big data, bioinformatics, and artificial intelligence and automation. The Dante Labs team has worked hard to advance medical and genetic research.
Dante Labs Whole Genome Sequencing
Dante Labs Whole Genome Sequencing is our main test and one of the most complete DNA tests available to consumers in the market. We analyze 100% of the DNA (the whole genome) and give actionable insights on:
- Reaction to 150 medications
- Predispositions to 180 health and wellness traits
- Personalized reports for rare diseases and family history diseases
Our AI-powered Personalized Reports
Our reports are customized on users' medical history, allowing individuals to make life-changing decisions. We developed an internal tool that analyzes individuals' medical diagnoses, medical records, or self-reported phenotype descriptions to generate the most relevant list of biomarkers from the whole genome data to include in a personalized report that is easy to understand. For instance, people with a diagnosis of epilepsy receive an Epilepsy Report as well as a broader report on neurodegenerative diseases customized on their actual diagnosis.
Our users can upload pdf files or even photos of the reports and our engine extracts the relevant information.
Dante Labs Whole GenomeZ
Dante Labs Whole GenomeZ is a whole genome sequencing test with a coverage of 130X on the Whole Exome (and standard 30X on the non-coding regions of the DNA), as broad as the WGS and as accurate as the WES. To our knowledge, we are the only company offering this test. Results include the same reports of our Whole Genome Sequencing test.
Dante Labs Whole GenomeL
Dante Labs Whole GenomeL is one of the first Long-Read Whole Genome Sequencing tests available commercially, based on long-read sequencing (also known as third-generation sequencing), leveraging Oxford Nanopore sequencing technology.
Dante Labs Whole GenomeL was the first test performed in Dante Labs own, Nanopore certified sequencing center.
Andrea and Mattia had created a web design agency in high school. Years later, Andrea had a friend who needed a whole genome sequencing test and asked Mattia for advice. Together, they realized that individuals lacked access to advanced genomics and decided to change this.
1 free Whole Genome Test for investors between $10,000 and $19,999
3 free Whole Genome Tests for investors between $20,000 and $24,999
5 free Whole Genome Tests for investors above $25,000
It is advised that you consult a tax professional to fully understand any potential tax implications of receiving investor perks before making an investment.
Frequently Asked Questions
When you complete your investment on SeedInvest, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by Dante Labs. Once Dante Labs accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to Dante Labs in exchange for your securities. At that point, you will be a proud owner in Dante Labs.
Preferred equity is usually issued to outside investors and carries rights and conditions that are different from that of common stock. For example, preferred equity may include rights that prevent or minimize the effects of dilution or grants special privileges in situations when the company is sold.
A convertible note is a unique form of debt that converts into equity, usually in conjunction with a future financing round. The investor effectively loans money to a startup with the expectation that they will receive equity in the company in the future at a discounted price per share when the company raises its next round of financing.
To learn more about startup investment types check out “How to Choose a Startup Investment” in our academy.
To make an investment, you will need the following information readily available:
- Personal information such as your current address and phone number
- Employment and employer information
- Net worth and income information
- Social Security Number or passport
- ABA bank routing number and checking account number (typically found on a personal check or bank statement)
Because Dante Labs is offering its securities under Rule 506(c) of Regulation D, your status as an Accredited Investor will also need to be verified and you will be asked to provide documentation supporting your income, net worth, revenue, or net assets or a letter from a qualified advisor such as a Registered Investment Advisor, Registered Broker Dealer, Lawyer, or CPA.
Until a closing occurs, you may cancel your investment at any time, for any reason. You will receive an email when the closing occurs and your securities have been issued. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To cancel your investment, please go to your portfolio page by clicking your profile icon in the top right corner.
Currently there is no market or liquidity for these securities. Right now Dante Labs does not plan to list these securities on a national exchange or another secondary market. At some point Dante Labs may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when Dante Labs either lists their securities on an exchange, is acquired, or goes bankrupt.
You can return to SeedInvest at any time to view your portfolio of investments and obtain a summary statement.
This is Dante Labs's fundraising profile page, where you can find information that may be helpful for you to make an investment decision in their company. The information on this page includes the company overview, team bios, and the risks and disclosures related to this investment opportunity.
This investment is highly speculative and should not be made by anyone who cannot afford to risk the entire investment amount. In addition to these risks, you should carefully consider the specific information and risks disclosed in Dante Labs’s profile.